NANG KUANG PHARM CO
GenericsNANG KUANG PHARM CO is a generic drug manufacturer focused on Infectious Disease, Dermatology, Oncology.
NANG KUANG PHARM CO at a Glance
- Fast trial execution (20 months median completion)
NANG KUANG PHARM CO's Key Drugs
NANG KUANG PHARM CO's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
NANG KUANG PHARM CO's Recent FDA Approvals
NANG KUANG PHARM CO secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
NANG KUANG PHARM CO's Therapeutic Areas
NANG KUANG PHARM CO's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NANG KUANG PHARM CO's Top Competitors
NANG KUANG PHARM CO's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and KING PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NANG KUANG PHARM CO Pipeline Snapshot
Active clinical trials for NANG KUANG PHARM CO across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 20 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2016-12-20
- Latest
- 2026-02-03
- Applications
- 5
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges